Company: BIAF
Filing Date: 2025-10-27
Form Type: PRER14A
Source: 0001493152-25-019752
Chunk: 4

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-27
Form: PRER14A
Chunk 4
---
 B Anti-Dilution Adjustment Proposal”).                                                                           |     | FOR            |     |        10 |
| Approval                                                                                                                                
 of an amendment to the 2024 Equity Incentive Plan (the “2024 Plan”) to increase the number of shares of                                 
 Common Stock reserved for issuance thereunder to 750,000 shares from 66,666 shares (the “Plan Amendment Proposal  ”).                   |     | FOR            |     |        11 |
| Authorization                                                                                                                           
 to issue securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d) (the “Offering               
 Proposal”).                                                                                                                             |     | FOR            |     |        16 |
| Approval of any change                                                                                                                  
 of control under Nasdaq Marketplace Rule 5635(d) that may result from the potential issuance of securities in the non-public offerings  
 (the “Change of Control Proposal”).                                                                                                     |     | FOR            |     |        17 |
| Approval                                                                                                                                
 of an adjournment of the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of       
 proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Warrant Exercise       
 Proposal, the Warrant Anti-Dilution Adjustment Proposal, the Series B Anti-Dilution Adjustment Proposal, Plan Amendment Proposal,       
 the Offering Proposal and/or the Change of Control Proposal (the “Adjournment Proposal”).                                               |     | FOR            |     |        18 |

Even if you plan to attend the Special Meeting, please vote in advance so that your vote will be counted if you later decide not to attend the Special Meeting.

| 1 |

<div align='center'>QUESTIONS AND ANSWERS ABOUT

THE PROXY MATERIALS AND THE SPECIAL MEETING</div>

Who is soliciting my vote?

The Board of Directors of bioAffinity Technologies, Inc. is soliciting your proxy to be used at the Special Meeting.

When and where will the Special Meeting be held?

The Special Meeting will be held on Friday, December 19, 2025, at 8:00 a.m. Central Time, at the Company’s principal office at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.

What do I need to do if I would like to attend the Special Meeting?

If you wish to attend the Special Meeting in person, you must present a valid form of photo identification